Lake Street analyst Brooks O’Neil initiated coverage of LifeMD (LFMD) with a Buy rating and $12 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- LifeMD initiated with a Neutral at Mizuho
- ADA advises doctors, patients not to use compounded GLP-1s
- Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s
- LifeMD price target raised to $12 from $11 at B. Riley